Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)

被引：0
|
作者：
Sandborn, William J.
Schreiber, Stefan
Hanauer, Stephen B.
Colombel, Jean-Frederic
Bloomfield, Ralph
Lichtenstein, Gary
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
44
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [31] Predictors of Response and Remission to Certolizumab Pegol in Patients With Crohn's Disease: Data From the WELCOME Study
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert R.
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Ernault, Etienne
    Fedorak, Richard N.
    Spehlmann, Martina
    Wolf, Douglas C.
    Lee, Scott D.
    Rutgeerts, Paul J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S164 - S164
  • [32] Remission Rates in Crohn's Disease Patients Treated With a Re-Induction Regimen of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From the Precise 4 Study
    Lee, Scott D.
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David G.
    Kayhan, Cem
    Kosutic, Gordana
    Ambarkhane, Sumeet
    Sen, David
    Hasan, Iram
    Spearman, Marshall
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S261 - S261
  • [33] The long-term, 30-month, efficacy and tolerability of Certolizumab Pegol Therapy for Crohn's Disease
    Sandborn, W.
    Lichtenstein, G.
    Schreiber, S.
    Feagan, B.
    [J]. INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S29 - S29
  • [34] Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease Who Have Failed Previous TNF Inhibitor Therapies
    Vermeire, Severine
    Howaldt, Stefanie
    Hommes, Daan
    Bressler, Brian
    Colombel, Jean-Frederic
    Mitchev, Krassimir
    Rutgeerts, Paul
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S416 - S416
  • [35] IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN'S DISEASE
    Lefevre, Pavine
    Guizzetti, Leonardo
    Feagan, Brian
    Pop, Anca
    Yassine, Mohamed
    Sandborn, William
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (03) : S113 - S114
  • [36] IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN'S DISEASE
    Lefevre, Pavine
    Guizzetti, Leonardo
    Feagan, Brian
    Pop, Anca
    Yassine, Mohamed
    Sandborn, William
    Vande Casteele, Niels
    [J]. INFLAMMATORY BOWEL DISEASES, 2020, 26 : S69 - S70
  • [37] PATIENTS WITH CROHN'S DISEASE AT RISK OF SUBTHERAPEUTIC CERTOLIZUMAB PEGOL DRUG EXPOSURE CAN BE IDENTIFIED PRIOR TO INITIATION OF THERAPY
    Lefevre, Pavine
    Guizzetti, Leonardo
    Feagan, Brian G.
    Pop, Anca
    Yassine, Mohamed
    Sandborn, William J.
    Vande Casteele, Niels
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S467 - S467
  • [38] Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
    Lee, Scott D.
    Rubin, David T.
    Sandborn, William J.
    Randall, Charles
    Younes, Ziad
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David
    Dassopoulos, Themos
    Arsenescu, Razvan
    Gutierrez, Alexandra
    Scherl, Ellen
    Kayhan, Cem
    Hasan, Iram
    Kosutic, Gordana
    Spearman, Marshall
    Sen, David
    Coarse, Jason
    Hanauer, Stephen
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) : 1870 - 1880
  • [39] Certolizumab Pegol is Effective at Maintaining Response and Remission in Patients With Fistulising Crohn's Disease: 3-Year Results From the PRECiSE 3 Study
    Schreiber, Stefan
    Lawrance, Ian C.
    Thomsen, Ole O.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [40] Long-term safety of an anti-TNF drug by duration of exposure compared to non-anti-TNF exposed patients with Crohn's disease: Novel data from the certolizumab pegol development program
    Lichtenstein, Gary R.
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2008, 134 (04) : A68 - A68
12345